Dr. Yeku is a Medical Oncologist extensively trained in the care and management of women with Gynecologic Malignancies. He applies a team-based, shared-decision making approach to the management of all his patients. He specializes in systemic treatment options, immunotherapy, investigational therapy, personalized medicine and palliative care.
- Centers & Specialties
- Clinical Interests
- Phase I Clinical Trials
- Translational research
- Translational research into rare gynecologic cancers
- Medical Education
- MD, PhD, Stony Brook University School of Medicine
- Residency, University of Pittsburgh Medical Center
- Fellowship, Memorial Sloan Kettering Cancer Center
- Board Certifications
- Internal Medicine
- Medical Oncology
- Foreign Languages
- Boston: Massachusetts General Hospital
- Insurances Accepted
- Aetna Health Inc.
- AllWays Health (NHP) - ACD
- AllWays Health (NHP) - PBO
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Maine Community Health Options (MCHO)
- Medicare - ACD
- OSW - Connecticut
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
- Provider Gender
Dr. Yeku completed his fellowship training at Memorial Sloan Kettering Cancer Center. During his fellowship, he trained in the Gynecologic Malignancies service and developed broad expertise in the management of GYN malignancies, including rare tumors such as clear cell and sarcomas. He is a fellow of the American College of Physicians. He has a Ph.D. in molecular and cellular pharmacology has received postdoctoral training in immunotherapy and adoptive cellular therapy. While at MSK, he conducted preclinical, translation and clinical research on Chimeric Antigen Receptor T-cells for ovarian cancer. His training and expertise include standard systemic treatment options, immunotherapy, targeted-therapy and immunotherapeutic modalities. As part of a multidisciplinary group, he works with Gynecologic Oncology surgeons, Radiation Oncologists, nurses and social workers to provide the state-of-the-art individualized therapy to this patients.
- Research Summary
Chimeric Antigen Receptor (CAR) T Cells for Ovarian Cancer
Chimeric Antigen Receptor (CAR) T cells have not been successful in the management of solid tumor malignancies. Reasons for this include; poor trafficking, the presence of an immunosuppressive tumor microenvironment, CAR T-cell dysfunction and immune escape via antigen-loss. We are developing strategies to further modify CAR T cells to optimize their efficacy for ovarian cancer and gynecologic malignancies. Our approaches to further engineering these CAR T cells are informed by the ovarian cancer tumor microenvironment. Using syngeneic immune competent mouse models and subsequent validation in genetically engineered and xenograft models, we are able to effectively evaluate these rationally optimized CAR T cells as monotherapy or in combination with other immunomodulatory agents prior to initiation of clinical trials.
1. Avanzi MP, Yeku O*#, Li X, Wijewarnasuriya DP, van Leeuwen DG, Cheung K, Park H, Purdon TJ, Daniyan AF, Spitzer MH, Brentjens RJ#. Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Rep. 2018;23(7):2130-41. PubMed PMID: 29768210; PMCID: PMC5986286. *Co-first author, # corresponding author
2. Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep. 2017;7(1):10541. PubMed PMID: 28874817; PMCID: PMC5585170.
3. Yeku O, Li X, Brentjens RJ. Adoptive T-Cell Therapy for Solid Tumors. Am Soc Clin Oncol Educ Book. 2017;37:193-204. PubMed PMID: 28561728; PMCID: PMC5549627.
4. Yeku OO, Brentjens RJ. Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochem Soc Trans. 2016;44(2):412-8. PubMed PMID: 27068948; PMCID: PMC5529098.
55 Fruit Street
Boston, MA 02114-2696